钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病合并心房颤动影响的研究进展  

Effects of SGLT2 inhibitors on atrial fibrillation induced by type 2 diabetes mellitus

作　　者：李承霖 刘飞 杨晓蕾[1] 夏云龙[1] LI Chenglin;LIU Fei;YANG Xiaolei(Department of Cardiovascular Medicine,The First Affiliated Hospital of Dalian Medical University,Dalian 116000,China)

机构地区：[1]大连医科大学附属第一医院心血管内科,116000

出　　处：《中国糖尿病杂志》2022年第5期391-394,共4页Chinese Journal of Diabetes

摘　　要：心房颤动(AF)是临床常见心律失常,显著增加脑卒中、心力衰竭等风险,严重危害人类健康。T2DM是常见慢性疾病之一,可增加AF风险,与AF患者心血管死亡风险增加相关。T2DM合并AF的病理生理机制尚不明确,可能与心房电、结构及自主神经重构相关。SGLT2i是一种新型降糖药,除有显著降糖效果外,还降低T2DM患者AF风险。本文对SGLT2i对T2DM合并AF影响的研究进展进行综述。Atrial fibrillation(AF)is one of the most common arrhythmia in clinic,which significantly increases the risk of stroke and heart failure,and seriously endangers human life and health.Type 2 diabetes mellitus(T2DM)is also one of the most common chronic diseases,and can significantly increase the incidence of AF.T2DM is also associated with an increased risk of cardiovascular and cerebrovascular death in AF patients.The pathophysiological mechanism of T2DM related AF is still unclear,but it may be related to electrical,structural and autonomic nerve remodeling.Sodium-glucose co-transporter 2 (SGLT2)inhibitors is a new hypoglycemic drug.Some clinical trials have proved that SGLT2i can significantly reduce the risk of AF in patients with T2DM.This paper reviews the research progress of the effect of SGLT2i on T2DM complicated with AF.

关 键 词：心房颤动 糖尿病 2型 SGLT2i 

分 类 号：R541.75[医药卫生—心血管疾病] R587.2[医药卫生—内科学]